Addressing Healthcare Fraud: Insights from Brian Blase and Regulatory Actions

Brian Blase, Ph.D., President of the Paragon Health Institute and former Special Assistant to the President for Economic Policy at the National Economic Council, has been actively involved in addressing healthcare policy challenges. Recently, the Trump administration launched a campaign against healthcare fraud, focusing on New York's Medicaid personal care program. Blase argues that fraud and abuse are deeply tied to the federal health program structures and incentives.

During his testimony before the Joint Economic Committee, Blase highlighted structural weaknesses in the Affordable Care Act (ACA) exchanges, Medicaid, and Medicare, which he believes lead to excessive spending and lack of accountability. He noted that Medicaid encourages state spending increases offset by federal contributions, which cover about 70% of total program expenses. This arrangement can result in improper expenses comprising approximately a quarter of the program's total commitments.

In the Medicare program, Blase identified financial incentives as a primary driver of exorbitant costs, rather than direct fraud, citing cases involving reimbursement for skin substitutes. His insights were elaborated upon at a Paragon Health Institute event, addressing improper ACA exchange enrollments due to weak verification standards and subsidy impacts. Experts, including Blase, projected that by 2026, a significant number of exchange enrollments might be improper.

Research by Liam Sigaud and Eric Sun examined how Medicaid provider taxes affect commercial hospital prices, revealing that providers often pass these taxes onto private insurers, thereby raising healthcare costs for consumers. This insight highlights the complex interplay between regulatory mechanisms and market dynamics in healthcare pricing.

The Department of Justice (DOJ) recently filed a lawsuit against New York State’s Medicaid program, alleging fraudulent practices in the Consumer Directed Personal Assistance Program. This case is part of broader Medicaid integrity issues that underscore fraud risks in Medicaid-funded services.

The DOJ's 2026 National Health Care Fraud Takedown resulted in numerous charges and asset seizures, addressing fraud across various programs, including Medicare and Medicaid. These actions demonstrate the government's commitment to enforcing regulatory compliance and protecting public healthcare funds from fraud and abuse.

These developments underscore vital issues within U.S. healthcare policy and regulation, warranting continuous reform and scrutiny to protect program integrity and ensure responsible public fund management.